FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 626 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Qué deben saber los latinos sobre dejar de fumar y las... November 19, 2021 Learning to Advocate for Yourself – An Important Skill! June 15, 2023 FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-mutated Metastatic... August 25, 2023 Keto Molecule Offers Clue for Preventing Colorectal Cancer June 2, 2022 Load more HOT NEWS Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and... EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... Tomorrow is National Prescription Drug Take-Back Day! 27-Year-Old Diagnosed with Cancer at 20 Weeks Pregnant Gives Birth Amid...
